Shots:

• The P-III ARCHES trial involves assessing of Xtandi + ADT (enzalutamide- 160mg) vs ADT monothx in 1-150 men with mHSPC at the US- Canada- EU- South America
• P-III ARCHES study results: reducing the risk of radiographic progression or death by 61%; reduced the risk of PSA progression- antineoplastic therapy & deterioration in urinary symptoms; Undetectable PSA (68.1% vs 17.6%); ORR (83.1% vs 63.7%); GRADE 3 or 4 AEs (23.6% vs 24.7%)
• Xtandi (enzalutamide) is an androgen receptor inhibitor targeted for astration-resistant prostate cancer. In Oct 2009- Pfizer & Astellas globally collaborated to jointly develop & commercialize enzalutamide in the US

Ref: Astellas | Image:Astellas